Introduction
Fine needle aspiration (FNA) and core needle (CN) biopsies are useful instruments in diagnosing soft tissue and bone tumors [1] . Both needle techniques are in most cases easy to perform, cost effective and well tolerated by the patient [2] . In Scandinavia, the further management of the patient is decided upon the pretreatment diagnosis made on tumor cells from FNA and/or tissue from CN biopsies, combined with clinical and radiographic information [3] . Apart from the morphologic evaluation of tumor cells in FNA and CN biopsies, ancillary techniques, such as immunocytochemistry/immunohistochemistry, are often used to improve the diagnostic precision. As several bone and soft tissue tumors are characterized by specific genetic changes, notably translocations resulting in fusion genes, also the genetic status of the tumor can provide clinically useful information [4] . To ensure robust and rapid results, these genetic abnormalities are usually investigated by fluorescence in situ hybridization (FISH) or reverse transcriptase polymerase chain reaction (RT-PCR) analysis. A drawback with both techniques is that they provide information only on the abnormality that is assessed, i.e., they can support or exclude a tentative diagnosis, but rarely suggest an alternate diagnosis. Furthermore, most bone and soft tissue tumors do not have any known specific genetic changes, but display characteristic combinations of numerical and unbalanced structural chromosome aberrations. For instance, if the cytologic examination cannot decisively settle whether a lesion is benign or malignant, the finding of a near-triploid chromosomes number with multiple structural and numerical changes strongly argues for the latter. Thus, the genomic screening obtained through chromosome banding analysis of cultured cells could provide further diagnostic information.
Most of the cytogenetic information on bone and soft tissue tumors, presently amounting to data on close to 3,000 cases [5] , comes from studies on ST biopsies, and very few attempts have been made to evaluate in larger series the possibility to obtain tumor karyotypes from needle biopsies [6] [7] [8] . In the present study, we have assessed the results from G-banding analysis of 114 FNA biopsies, and compare the results with those from the corresponding ST biopsies. In addition, we also compared with preliminary data on 31 CN biopsies.
Materials and Methods
The study was based on fresh FNA (n=114), CN (n=31) and ST (n=138) biopsies obtained from a total of 139 patients with a bone or soft tissue tumor treated at the tumor orthopedic centre, Lund University Hospital, Lund, Sweden, between 1987 and 2009. Clinical information, histopathologic diagnoses and tumor karyotypes are given in Tables 1 and 2. The FNA procedures were performed with 22-24 gauge needles attached to disposable, 10-mL syringes in a Cameco syringe holder (Cameco AB Sandviken, Sweden). The aspirates were air dried, stained with May-Grünwald-Giemsa (MGG), fixed in 95% ethanol, and stained with hematoxylin and eosin (H&E). The number of passes varied from 1 to 6 with an average of 3. Between 1987 and 1997 no separate passes for cytogenetic analysis were performed and the material derived from needle rinsing. From 1997, one separate pass for cytogenetic material was performed. Other changes introduced during the sampling period included trials with cellblocks between 1995 and 1997; since 1997, the cellblock technique is routine. In 2002, liquid-based immunocytology was introduced as a routine diagnostic method. The sampling was performed by the cytopathologist in the majority of the cases. However, sampling of non-palpable lesions was performed in collaboration between the cytopathologist and a radiologist using image guidance, usually ultrasound. Rapid evaluation of the adequacy of the material with quick staining (DiffQuick or H&E) started in 1997 with selected cases and became routine in 2000. Concerning the material sent for cytogenetic analysis no specific rapid evaluation of the quantity or quality was performed. The CNB procedures were performed using an 18-gauge needle and the Pro-Mag™ 1,4 and 2,5 Automatic Biopsy Instrument. After washing the skin with 70% ethanol, local anesthesia was achieved by subcutaneous infiltration of 1-3 mL 1% lidocaine.
Short-term cell culturing, harvesting, and G-banding of chromosomes were performed as described [9] , and the karyotypes were interpreted and written according to ISCN (2009) [10] . The cytogenetic analysis was considered successful if a clonal acquired aberration was detected.
Results
Of the 138 ST biopsies, 88 (64%) showed clonal acquired chromosome aberrations, 42 (30%) displayed a normal karyotype, and 8 (6%) did not yield any karyotype due to infection or poor cell growth. The corresponding figures for the 114 FNA biopsies were 27 (24%), 28 (25%), and 59 (52%), and for the 31 CN biopsies 15 (48%), 10 (32%), and 6 (19%) ( Tables 3 and 4 ). When comparing benign and malignant tumors (here defined as tumors labeled sarcomas), abnormal karyotypes were seen in 14% and 28% of FNA samples, respectively ( Table 5 ). Of the 27 FNA biopsies with clonal aberrations, 17 showed an identical or very similar karyotype in the ST biopsies, 3 displayed seemingly unrelated clones in the ST biopsies, 5 did not show any clonal changes in the ST biopsies, and in 2 cases there was no corresponding ST biopsies.
Of the 15 CN biopsies with clonal aberrations, 8 showed an identical or very similar karyotype in the ST biopsies, 2 displayed seemingly unrelated clones in the ST biopsies, 3 did not show any clonal changes in the ST biopsies, and for 2 samples there was no corresponding ST biopsies.
Discussion
The main aim of the present study was to evaluate the success rate for chromosome banding analysis of cells from FNA biopsies from bone and soft tissue tumors. For that purpose, karyotypes from 114 FNA biopsies from 111 patients were retrieved and compared with the results of ST biopsies from the corresponding tumors. The overall success rate for cytogenetic analysis on material provided from FNA was low in our material. Only in 24% of the samples was an abnormal karyotype identified, compared to 64% of the ST biopsy material. Nor were any major differences seen when subdividing the material according to the origin of the tumor, bone vs soft tissue, or whether they were benign or malignant (Tables 3-5 ). Thus, the results on FNA biopsies were consistently poor, CN biopsies showed better and ST biopsies the best results.
Bone and soft tissue tumors are histologically heterogeneous, and only for a few subgroups did the number of investigated cases allow for an attempt to compare the cytogenetic success rate with lineage of differentiation ( Table 6 ). The only group of tumors that showed a notably higher fraction of abnormal karyotypes was Ewing sarcoma/primitive neuroectodermal tumors; an abnormal karyotype was found in 6, including one case with a single abnormal cell, of the 11 FNA samples. This finding is in agreement with previous data [8] . The group that showed the lowest success rate and the highest failure rate was the adipose tissue tumors. This could be attributed to the characteristics of adipose tumor tissue which makes it difficult to aspirate adequate sample material. In spite of the relatively high success rate in Ewing tumors, one must conclude that chromosome banding analysis of cells from FNA biopsies is not a cost-effective method to search for genetic information of diagnostic relevance in the management of patients with bone and soft tissue tumors. This conclusion does not, of course, apply to the directed analyses. Both FISH and RT-PCR have been shown to be very useful when searching for specific neoplasiaassociated rearrangements, such as fusion genes, in samples with small numbers of tumor cells [11, 12] .
The reason(s) for the relatively poor success rate for chromosome banding analysis of FNA biopsies is not known, but the sheer quantity of tumor cells might be one factor. In support of this notion, the, admittedly preliminary, data on 31 CN biopsies suggest that already this relatively small increase in sample size results in a much higher success rate. An abnormal karyotype was found in 15 of 31 (48%) CN biopsies, to be compared with 24% of FNA biopsies and 64% of ST biopsies.
What other options, then, exist for obtaining a preoperative genomic tumor screening? Although array-based technologies for either global gene expression patterns or genomic imbalances are potentially very powerful screening methods, they are still used mainly as research tools, and their limitations with regard to the size and quality of the tumor samples have been poorly explored. Nevertheless, there are some promising results on FNA material from papillary thyroid carcinoma and non-small cell lung carcinomas [13] [14] [15] . The same techniques should be applicable also to soft tissue and bone tumors, but further studies are needed to evaluate this.
Still, the present study suggests that CN biopsies are more promising than FNA biopsies in this context. Also CN is well tolerated by the patient, cost effective and relatively easy to perform [2, 16] . In addition, CN biopsies provide better information on the architecture of the tumor tissue, as well as more reliable material for ancillary techniques such as immunohistochemistry, FISH and RT-PCR.
FNA can provide diagnostic smears for musculoskeletal lesions but as a standalone method for further evaluation it has limitations [17] . In our opinion, FNA and CN complement each other as diagnostic instruments for cytomorphologic evaluation, but when it comes to genetic screening through chromosome banding analysis CN seems superior to FNA. However, one should not forget the possibility to use ancillary techniques directly on FNA material, which can prove to be useful [18] .
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